BioXcel Therapeutics, Inc. Logo

BioXcel Therapeutics, Inc.

Biopharmaceutical company using AI to develop drugs for neuroscience and immuno-oncology.

BTAI | US

Overview

Corporate Details

ISIN(s):
US09075P2048
LEI:
Country:
United States of America
Address:
555 LONG WHARF DRIVE, 6511 NEW HAVEN

Description

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company that utilizes a proprietary artificial intelligence (AI) platform for drug development. The company focuses on creating transformative medicines in the fields of neuroscience and immuno-oncology. Its AI-driven approach aims to identify new therapeutic uses for existing molecules and novel compounds, potentially accelerating development timelines. The company's lead commercial product is IGALMI™ (dexmedetomidine sublingual film), approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BioXcel's late-stage clinical pipeline includes programs investigating treatments for agitation in patients with Alzheimer's disease and other neuropsychiatric conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all BioXcel Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioXcel Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioXcel Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.